Results 151 to 160 of about 10,576 (193)
Some of the next articles are maybe not open access.
Expert Opinion on Pharmacotherapy, 2005
Perindopril is a third-generation ACE inhibitor that is characterised as a small, lipophilic molecule with a therapeutically active carboxyl side group. These and other features combine to make this a unique member of a very well-established class of drugs that have proven efficacy in a wide range of cardiovascular diseases.
K, Alfakih, A S, Hall
+5 more sources
Perindopril is a third-generation ACE inhibitor that is characterised as a small, lipophilic molecule with a therapeutically active carboxyl side group. These and other features combine to make this a unique member of a very well-established class of drugs that have proven efficacy in a wide range of cardiovascular diseases.
K, Alfakih, A S, Hall
+5 more sources
Perindopril for the treatment of hypertension
INTRODUCTION: Treatment of hypertension is fundamental for the prevention of cardiovascular events and mortality. This review focuses on the specific benefits of the ACE inhibitor perindopril.
Lorenzo Ghiadoni
exaly +2 more sources
Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease
The angiotensin-converting enzyme (ACE) inhibitor perindopril (Coversyl) is a long-acting lipophilic drug with a high-tissue affinity for the ACE.
Jasper J Brugts, Roberto Ferrari
exaly +2 more sources
Oculohypotensive effect of perindopril in acute and chronic models of glaucoma in rabbits
We studied the effect of perindopril (1%) on intraocular pressure (IOP) and compared it with the effect of pilocarpine, a therapeutic agent used in experimentally induced acute and chronic models of glaucoma in rabbits.
Gaurang Shah, Ramesh K Goyal, Laxmi Iyer
exaly +2 more sources
Drugs, 2002
Perindopril is a long-acting ACE inhibitor, acting through its only active metabolite perindoprilat. It inhibits the renin-angiotensin system by preventing both the conversion of angiotensin I to angiotensin II and the degradation of bradykinin, thereby reducing the vasoconstriction and left ventricular remodelling characteristic of heart failure ...
Dene, Simpson +2 more
+5 more sources
Perindopril is a long-acting ACE inhibitor, acting through its only active metabolite perindoprilat. It inhibits the renin-angiotensin system by preventing both the conversion of angiotensin I to angiotensin II and the degradation of bradykinin, thereby reducing the vasoconstriction and left ventricular remodelling characteristic of heart failure ...
Dene, Simpson +2 more
+5 more sources
Heart disease (Hagerstown, Md.), 2001
Perindopril is the newest angiotensin-converting enzyme inhibitor to be approved in the United States. It is indicated for the treatment of essential hypertension either alone or in combination with other antihypertensives, especially thiazide diuretics. Perindopril must be converted to perindoprilat, its active metabolite.
D C, O'Loughlin, V L, Chu, D, Singh
openaire +1 more source
Perindopril is the newest angiotensin-converting enzyme inhibitor to be approved in the United States. It is indicated for the treatment of essential hypertension either alone or in combination with other antihypertensives, especially thiazide diuretics. Perindopril must be converted to perindoprilat, its active metabolite.
D C, O'Loughlin, V L, Chu, D, Singh
openaire +1 more source

